CN103261193A - 抑制白三烯生成的*二唑抑制剂 - Google Patents

抑制白三烯生成的*二唑抑制剂 Download PDF

Info

Publication number
CN103261193A
CN103261193A CN2011800565586A CN201180056558A CN103261193A CN 103261193 A CN103261193 A CN 103261193A CN 2011800565586 A CN2011800565586 A CN 2011800565586A CN 201180056558 A CN201180056558 A CN 201180056558A CN 103261193 A CN103261193 A CN 103261193A
Authority
CN
China
Prior art keywords
alkyl
substituted
pharmaceutically acceptable
optionally
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800565586A
Other languages
English (en)
Chinese (zh)
Inventor
A·巴托洛兹
T·伯萨纳克
陈志东
S·德洛姆贝特
J·A·丹斯
J·D·休伯
刘为民
P·L·洛克
T·M·莫维克
A·奥拉格
D·里瑟
H·泰伊
吴立芬
R·M·津德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44720163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103261193(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN103261193A publication Critical patent/CN103261193A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2011800565586A 2010-09-23 2011-09-20 抑制白三烯生成的*二唑抑制剂 Pending CN103261193A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38573310P 2010-09-23 2010-09-23
US61/385,733 2010-09-23
US201161533349P 2011-09-12 2011-09-12
US61/533,349 2011-09-12
PCT/US2011/052254 WO2012040139A1 (en) 2010-09-23 2011-09-20 Oxadiazole inhibitors of leukotriene production

Publications (1)

Publication Number Publication Date
CN103261193A true CN103261193A (zh) 2013-08-21

Family

ID=44720163

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800565586A Pending CN103261193A (zh) 2010-09-23 2011-09-20 抑制白三烯生成的*二唑抑制剂

Country Status (19)

Country Link
US (1) US8575201B2 (enExample)
EP (1) EP2619197B1 (enExample)
JP (1) JP5713511B2 (enExample)
KR (1) KR20130109122A (enExample)
CN (1) CN103261193A (enExample)
AU (1) AU2011305667A1 (enExample)
BR (1) BR112013008638A2 (enExample)
CA (1) CA2812449A1 (enExample)
CL (1) CL2013000788A1 (enExample)
CO (1) CO6710902A2 (enExample)
EA (1) EA201300389A1 (enExample)
EC (1) ECSP13012548A (enExample)
IN (1) IN2013DN02555A (enExample)
MX (1) MX2013003202A (enExample)
PE (1) PE20131398A1 (enExample)
PH (1) PH12013500545A1 (enExample)
SG (1) SG188604A1 (enExample)
WO (1) WO2012040139A1 (enExample)
ZA (1) ZA201301747B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3150164B2 (ja) 1991-05-01 2001-03-26 電気化学工業株式会社 セメント混和材及びセメント組成物
WO2012027322A1 (en) * 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
CN103261193A (zh) 2010-09-23 2013-08-21 贝林格尔.英格海姆国际有限公司 抑制白三烯生成的*二唑抑制剂
JP5828188B2 (ja) * 2010-09-23 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のオキサジアゾール阻害剤
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
EP3070085B1 (en) * 2013-02-04 2019-01-09 Janssen Pharmaceutica NV Flap modulators
PL2875736T3 (pl) 2013-11-26 2017-02-28 Citrage N-karbamoiloputrescyna do zwiększenia syntezy białka mięśni

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1835755A (zh) * 2003-08-13 2006-09-20 希龙公司 Gsk－3抑制剂及其用途
WO2008030369A1 (en) * 2006-09-01 2008-03-13 Merck & Co., Inc. Inhibitors of 5 -lipoxygenase activating protein ( flap)
US20090192171A1 (en) * 2005-11-04 2009-07-30 Amira Pharmaceuticals, Inc. 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors
WO2010017870A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische triazolderivate zur behandlung von tumoren

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1188410C (zh) 1999-08-06 2005-02-09 詹森药业有限公司 非类固醇类的il－5抑制剂,其制备的方法以及包含该抑制剂的医药组合物
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
EP1814877B1 (en) 2004-10-18 2009-03-11 Merck & Co., Inc. Diphenyl substituted alkanes as flap inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
WO2007120574A2 (en) 2006-04-11 2007-10-25 Merck & Co., Inc. Diaryl substituted alkanes
EP2037928B1 (en) 2006-06-26 2012-01-11 Amgen Inc. Methods for treating atherosclerosis
EP2148878A4 (en) 2007-04-20 2011-08-10 Merck Canada Inc NEW HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE
EP2170065A4 (en) 2007-06-20 2011-11-23 Merck Sharp & Dohme DIPHENYL SUBSTITUTED ALKANES
JP2011500563A (ja) 2007-10-10 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション ジフェニル置換されたシクロアルカン
MX2011004570A (es) * 2008-10-31 2011-06-17 Merck Sharp & Dohme Antagonistas del receptor p2x3 para el tratamiento del dolor.
CA2749893A1 (en) 2009-02-04 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
KR20130079429A (ko) 2010-05-12 2013-07-10 벤더르빌트 유니버시티 헤테로시클릭 설폰 mglur4 알로스테릭 강화제, 조성물 및 신경 기능이상을 치료하는 방법
CN103180314A (zh) * 2010-08-16 2013-06-26 贝林格尔.英格海姆国际有限公司 抑制白三烯产生的*二唑类抑制剂
WO2012027322A1 (en) * 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
JP5828188B2 (ja) * 2010-09-23 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のオキサジアゾール阻害剤
CN103261193A (zh) 2010-09-23 2013-08-21 贝林格尔.英格海姆国际有限公司 抑制白三烯生成的*二唑抑制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1835755A (zh) * 2003-08-13 2006-09-20 希龙公司 Gsk－3抑制剂及其用途
US20090192171A1 (en) * 2005-11-04 2009-07-30 Amira Pharmaceuticals, Inc. 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors
WO2008030369A1 (en) * 2006-09-01 2008-03-13 Merck & Co., Inc. Inhibitors of 5 -lipoxygenase activating protein ( flap)
WO2010017870A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische triazolderivate zur behandlung von tumoren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
朱武生，等: "5脂氧合酶激活蛋白介导人脐静脉内皮细胞氧化损伤", 《中国动脉硬化杂志》, vol. 16, no. 6, 31 December 2008 (2008-12-31), pages 457 - 460 *

Also Published As

Publication number Publication date
US20120295896A1 (en) 2012-11-22
US8575201B2 (en) 2013-11-05
JP2013537909A (ja) 2013-10-07
SG188604A1 (en) 2013-04-30
AU2011305667A1 (en) 2013-03-21
CA2812449A1 (en) 2012-03-29
PH12013500545A1 (en) 2013-05-06
JP5713511B2 (ja) 2015-05-07
IN2013DN02555A (enExample) 2015-08-07
MX2013003202A (es) 2013-04-24
EP2619197A1 (en) 2013-07-31
WO2012040139A1 (en) 2012-03-29
PE20131398A1 (es) 2013-12-19
KR20130109122A (ko) 2013-10-07
CL2013000788A1 (es) 2013-06-28
CO6710902A2 (es) 2013-07-15
ECSP13012548A (es) 2013-06-28
BR112013008638A2 (pt) 2016-06-21
ZA201301747B (en) 2014-08-27
EP2619197B1 (en) 2015-08-05
EA201300389A1 (ru) 2013-09-30

Similar Documents

Publication Publication Date Title
TWI836159B (zh) 可作為helios蛋白質抑制劑之化合物
JP7076432B2 (ja) Ｈｐｋ１調節薬としてのピラゾロピリジン誘導体及びがんの治療のためのその用法
CN111377917B (zh) 杂环类化合物、中间体、其制备方法及应用
JP5862669B2 (ja) ロイコトリエン産生のオキサジアゾール阻害剤
JP5690839B2 (ja) ロイコトリエン産生のベンゾイミダゾール阻害薬
TWI867287B (zh) 經吡啶基取代之側氧基異吲哚啉化合物
CN105339368A (zh) 3-芳基-取代的咪唑并[1,2-a]吡啶及其用途
TW201217362A (en) Heteroaryls and uses thereof
CN106573906A (zh) 哌啶‑二酮衍生物
TW201238947A (en) Oxadiazole inhibitors of leukotriene production
CN103261193A (zh) 抑制白三烯生成的*二唑抑制剂
CN103402995B (zh) 吲哚、吲唑衍生物或其盐
TW201522330A (zh) ２－醯胺噻唑衍生物或其鹽
TW202003472A (zh) 鈣蛋白酶(calpain)調節劑及其醫療用途
US8580825B2 (en) Oxadiazole inhibitors of leukotriene production
CN112513041B (zh) 三环化合物
CN108779100A (zh) 3,4-二吡啶基吡唑类衍生物、其制备方法及其在医药上的应用
WO2023036252A1 (zh) 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
TW202525792A (zh) 經取代之側氧異吲哚啉基哌啶－２，６－二酮化合物
HK1183300A (en) Oxadiazole inhibitors of leukotriene production
CN111217816B (zh) 一类flt3激酶抑制剂及其制备和应用
WO2022253081A1 (zh) 氧化膦衍生物及其制备方法和应用
CN118715015A (zh) 选择性phd1抑制剂化合物、组合物和使用方法
HK40048952A (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
HK40039964B (zh) 三环化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1183300

Country of ref document: HK

C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130821

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1183300

Country of ref document: HK